Literature DB >> 20732955

Comprehensive analysis of sequence-specific stability of siRNA.

Junmei Hong1, Yuanyu Huang, Jun Li, Fan Yi, Jie Zheng, Huang Huang, Na Wei, Yongqiang Shan, Mingrui An, Hongyan Zhang, Jianguo Ji, Peizhuo Zhang, Zhen Xi, Quan Du, Zicai Liang.   

Abstract

Double-stranded small interfering RNAs (siRNAs) are important modulators of biological processes and hold great promise for therapeutic applications. However, serum processing of synthetic siRNAs is still largely unknown. To address this issue, serum degradation assays of 125 siRNAs were first performed in this study. Four siRNA categories of distinct serum stability were identified, including a group of siRNAs that were stable in their native form for both in vitro and in vivo assays. Fine mapping of the cleavage events occurring in serum treatment demonstrated that most occurred at two vulnerable sites, leading to a speculation that rational modification of these sites might protect most siRNAs from serum degradation. For proof of concept, an exhaustive siRNA modification study was performed. In addition to the consistent stabilization pattern revealed at these sites, our study further showed that a single modification made at the cleavage site stabilized the siRNAs to a large extent, highlighting the importance of these sites in siRNA degradation. In summary, the present study provided a comprehensive picture of serum processing of siRNA as well as a starting point for a rational siRNA modification strategy, both of which are of great importance to in vivo and therapeutic applications of siRNA.

Mesh:

Substances:

Year:  2010        PMID: 20732955     DOI: 10.1096/fj.09-142398

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  15 in total

1.  Elimination pathways of systemically delivered siRNA.

Authors:  Yuanyu Huang; Junmei Hong; Shuquan Zheng; Yi Ding; Shutao Guo; Hongyan Zhang; Xiuqin Zhang; Quan Du; Zicai Liang
Journal:  Mol Ther       Date:  2010-11-30       Impact factor: 11.454

2.  siRNA Design and GalNAc-Empowered Hepatic Targeted Delivery.

Authors:  Mei Lu; Mengjie Zhang; Bo Hu; Yuanyu Huang
Journal:  Methods Mol Biol       Date:  2021

Review 3.  Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology.

Authors:  Peixuan Guo; Farzin Haque; Brent Hallahan; Randall Reif; Hui Li
Journal:  Nucleic Acid Ther       Date:  2012-08       Impact factor: 5.486

4.  Probing the inherent stability of siRNA immobilized on nanoparticle constructs.

Authors:  Stacey N Barnaby; Andrew Lee; Chad A Mirkin
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-19       Impact factor: 11.205

Review 5.  Progress toward in vivo use of siRNAs-II.

Authors:  Garrett R Rettig; Mark A Behlke
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

Review 6.  RNA-based therapeutics for colorectal cancer: Updates and future directions.

Authors:  Jingwen Liu; Bin Guo
Journal:  Pharmacol Res       Date:  2019-12-19       Impact factor: 7.658

Review 7.  Stable RNA nanoparticles as potential new generation drugs for cancer therapy.

Authors:  Yi Shu; Fengmei Pi; Ashwani Sharma; Mehdi Rajabi; Farzin Haque; Dan Shu; Markos Leggas; B Mark Evers; Peixuan Guo
Journal:  Adv Drug Deliv Rev       Date:  2013-11-22       Impact factor: 15.470

8.  Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering.

Authors:  Jesper B Bramsen; Jørgen Kjems
Journal:  Front Genet       Date:  2012-08-20       Impact factor: 4.599

9.  Design of siRNA Therapeutics from the Molecular Scale.

Authors:  Phillip Angart; Daniel Vocelle; Christina Chan; S Patrick Walton
Journal:  Pharmaceuticals (Basel)       Date:  2013

10.  Systemic Administration of siRNA via cRGD-containing Peptide.

Authors:  Yuanyu Huang; Xiaoxia Wang; Weiyan Huang; Qiang Cheng; Shuquan Zheng; Shutao Guo; Huiqing Cao; Xing-Jie Liang; Quan Du; Zicai Liang
Journal:  Sci Rep       Date:  2015-08-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.